Daewoong Pharmaceutical Secures U.S. Patent for Core mRNA Technology, Making a Bid to Out-License Rejuvenation Technology

Daewoong Pharmaceutical has been notified of a decision to grant a U.S. patent for ionizable lipid, a core technology for mRNA delivery. The patent covers the foundational technology for its lipid nanoparticle (LNP) delivery platform, eTurna, including an ionizable lipid structure that delivers therapeutic nucleic acid materials to target cells. Once formal registration is completed, Daewoong Pharmaceutical will secure exclusive technology rights in the world’s largest pharmaceutical market and plans to use them to begin full-scale out-licensing negotiations for its rejuvenation pipeline.

eTurna and its underlying technology, ERA (Epigenetic Reprogramming of Aging), are assets Daewoong Pharmaceutical acquired from U.S. biotechnology company Turn Biotechnologies in May 2026. ERA is a partial reprogramming technology that injects “reprogramming” factors into aged cells in the form of mRNA, restoring only their functions to a younger state while preserving the cells’ inherent identities. eTurna is the name of the LNP platform that carries these factors.

Why ionizable lipids are critical

Because mRNA is easily degraded in the body, LNP technology is essential for safely transporting it to target cells. Ionizable lipids form the backbone of LNPs and are a key material that determines mRNA delivery efficiency and safety, making them one of the most difficult foundational technologies to develop in mRNA drug development. Since the effectiveness of mRNA-LNP technology was demonstrated through COVID-19 vaccines, competition has rapidly expanded into targeted therapies for cancer, autoimmune diseases and rejuvenation.

According to preclinical data included in the patent specification, administration of the LNPs to human dermal fibroblasts and aged tissue substantially increased expression of collagen VII, a marker of skin regeneration, and cell proliferation, while clearly reducing markers of aging. High delivery efficiency and cell viability were also confirmed in immune cells, including T cells. The data were presented as evidence supporting the potential to expand indications from skin regeneration to autoimmune diseases and intractable age-related diseases.

Global market size and out-licensing leverage

According to market research organizations including Global Market Insights (GMI), the global mRNA therapeutics market is expected to grow at an average annual rate of more than 14% from approximately $15.5 billion in 2024 to approximately $58.9 billion in 2034, or about 80 trillion won. Precedence Research projects that the rejuvenation therapeutics market alone will grow to approximately $9.3 billion, or about 14 trillion won, by 2035. Industry experts assess that Daewoong Pharmaceutical’s early acquisition of a U.S. patent for ionizable lipids, one of the most challenging technologies, will serve as a powerful negotiating card in future out-licensing discussions with multinational pharmaceutical companies.

Some also view the development as an example of South Korea’s pharmaceutical industry moving beyond its previous focus on generics and biosimilars into next-generation innovative, first-in-class drugs. Daewoong Pharmaceutical has emerged as a major player in the global mRNA market in a short period through an open innovation strategy that involves proactively acquiring core assets and intellectual property from local U.S. biotechs and combining them with its own R&D capabilities.

Clinical entry is the next hurdle

However, securing a patent does not guarantee commercial success. The next key challenge is entering clinical trials to demonstrate whether the rejuvenation effects observed in preclinical studies can be reproduced in humans without adverse effects. Daewoong Pharmaceutical CEO Sung-soo Park said, “We will combine validated foundational technologies with our R&D capabilities to promptly advance our preclinical pipelines into clinical development and prove our corporate value by developing rejuvenation drugs that lead the global market.” Whether the preclinical data can be reproduced in humans is expected to be the biggest turning point for future growth in the company’s value.